Abstracts

Switching From a Second-Line Boosted PI Regimen to B/F/TAF: Results of a Randomized Clinical Trial

Background: Patients on second-line boosted PI-based regimens in resource-limited settings have high rates of NRTI resistance, but this information is unknown in routine clinical care. This study compared continuing boosted PI + NRTIs vs bictegravir/tenofovir alafenamide/emtricitabine (B/F/TAF) in PWH on second-line ART with no prior drug resistance testing. Methods: This prospective, open-label trial conducted at…

Discovery of MK-8527: A Long-Acting HIV-1 Nucleoside Reverse Transcriptase Translocation Inhibitor

Background: Nucleoside reverse transcriptase translocation inhibitors (NRTTIs) such as islatravir (ISL) are potent inhibitors of HIV-1 replication. We have invented a novel NRTTI with antiviral potency and pharmacokinetics (PK) suitable for less-frequent-than-daily dosing, an attractive profile for HIV pre-exposure prophylaxis. MK-8527 is a 7-deaza-deoxyadenosine analog and is phosphorylated intracellularly to its active triphosphate (TP) form,…

Preclinical Characterization of GS-5894, a Potent NNRTI With Once-Weekly Oral Dosing Potential

Background: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) target an allosteric binding pocket near the polymerase active site of HIV-1 reverse transcriptase (RT) to prevent viral replication. To date, all approved NNRTIs must be dosed once-daily as part of a highly active antiretroviral regimen. Due to their physiochemical properties such as low solubility and high logD, NNRTIs…

The Preclinical Profile of Maturation Inhibitor VH3739937

Background: VH3739937 (VH937) is a next generation maturation inhibitor (MI) currently in clinical trials. We report here on its preclinical profile. Methods: Replication competent and single cycle inhibition assays were performed using a cohort of clinical isolates or site-directed mutant (SDM) viruses. Biochemical experiments using purified viral like particles (VLPs) were performed, while a radiolabeled…

Predictors of Injection Visit Adherence in Those Receiving Injectable Cabotegravir/Rilpivirine

Background: Long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) provides a novel treatment option for people with HIV (PWH). However, missed and late injections potentially jeopardize viral suppression, increases risk of resistance development, and requires extensive resources to track adherence and proactively reschedule missed injections. Methods: We conducted a retrospective cohort study at the University of California San…

Acceptability of Long-Acting Cabotegravir & Rilpivirine in a Large Urban Ambulatory HIV Clinic

Background: There are limited data regarding the acceptability of injectable long-acting cabotegravir and rilpivirine (LA-CAB/RPV) outside of randomized controlled trials (RCTs). We performed a mixed-methods analysis to describe patient-reported outcomes (PROs) of LA-CAB/RPV among a population often underrepresented in RCTs at one of the largest HIV/AIDS care centers in the United States. Methods: We interviewed…

Effect of Broadly Neutralizing Antibody Exposure on HIV Rebound Following Combination Immunotherapy

Background: Waning broadly neutralizing antibody (bNAb) levels and emergence of resistance have been associated with viral rebound during analytic treatment interruption (ATI) studies. In this pharmacokinetic/pharmacodynamic (PK/PD) analysis, we evaluated the impact of bNAb exposure, susceptibility, and antidrug antibody (ADA) formation on rebound kinetics following combination immunotherapy with a boosted DNA vaccine, lefitolimod, and bNAbs…